(Q33584240)

English

Risk of pneumocystosis after early discontinuation of prophylaxis among HIV-infected patients receiving highly active antiretroviral therapy

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Risk of pneumocystosis after early discontinuation of prophylaxis among HIV-infected patients receiving highly active antiretroviral therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

anti-retroviral agent

0 references

object named as

Szu-Min Hsieh

3

0 references

Wang-Huei Sheng

object named as

Wang-Huei Sheng

4

0 references

object named as

Hsin-Yun Sun

5

0 references

Chien-Ching Hung

object named as

Chien-Ching Hung

8

0 references

author name string

Chien-Yu Cheng

1

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Mao-Yuan Chen

2

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Yi-Chun Lo

6

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Wen-Chun Liu

7

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

publication date

21 May 2010

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

BMC Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

126

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2885390

21 June 2018

Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2885390

21 June 2018

Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2885390

21 June 2018

Pneumocystis pneumonia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2885390

21 June 2018

Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2885390

21 June 2018

Cotrimoxazole prophylaxis in adults infected with HIV in low-income countries.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2885390

21 June 2018

Pulmonary manifestations of HIV infection in the era of highly active antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2885390

21 June 2018

Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2885390

21 June 2018

Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2885390

21 June 2018

The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2885390

21 June 2018

A prospective multicentre study of discontinuing prophylaxis for opportunistic infections after effective antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-10-126

21 January 2018

Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-10-126

21 January 2018

Discontinuation of Pneumocystis carinii prophylaxis in patients infected with human immunodeficiency virus: a meta-analysis and decision analysis

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-10-126

21 January 2018

Clinical spectrum, morbidity, and mortality of acquired immunodeficiency syndrome in Taiwan: a 5-year prospective study

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-10-126

21 January 2018

Long-term safety of discontinuation of secondary prophylaxis against Pneumocystis pneumonia: prospective multicentre study

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-10-126

21 January 2018

Incidence of neutropenia in HIV-infected African adults receiving co-trimoxazole prophylaxis: a 6-year cohort study in Abidjan, Côte d'Ivoire

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-10-126

21 January 2018

Safe discontinuation of primary pneumocystis prophylaxis in Southern Indian HIV-infected patients on highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-10-126

21 January 2018

Discontinuation of primary prophylaxis in HIV-infected patients at high risk of Pneumocystis carinii pneumonia: prospective multicentre study

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-10-126

21 January 2018

Does cotrimoxazole prophylaxis for the prevention of HIV-associated opportunistic infections select for resistant pathogens in Kenyan adults?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2885390

31 October 2018

Improved survival of persons with human immunodeficiency virus type 1 infection in the era of highly active antiretroviral therapy in Taiwan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2885390

31 October 2018

Severe cutaneous reactions to sulfadoxine-pyrimethamine and trimethoprim-sulfamethoxazole in Blantyre District, Malawi

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2885390

31 October 2018

A community-based study of the incidence of trimethoprim-sulfamethoxazole-preventable infections in Malawian adults living with HIV.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2885390

31 October 2018

Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy?

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-10-126

21 January 2018

A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to > 200 × 106/l

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-10-126

21 January 2018

A Randomized Trial of the Discontinuation of Primary and Secondary Prophylaxis againstPneumocystis cariniiPneumonia after Highly Active Antiretroviral Therapy in Patients with HIV Infection

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-10-126

21 January 2018

Balancing individual benefit against public health risk: the impact of cotrimoxazole prophylaxis in HIV-infected patients on antimicrobial resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2885390

31 October 2018

Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection. HIV Outpatient Study (HOPS) Investigators

1 reference

https://pubmed.ncbi.nlm.nih.gov/20492660

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk for preventable opportunistic infections in persons with AIDS after antiretroviral therapy increases CD4+ T lymphocyte counts above prophylaxis thresholds

1 reference

https://pubmed.ncbi.nlm.nih.gov/20492660

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidemiology of Pneumocystis carinii pneumonia in an era of effective prophylaxis: the relative contribution of non-adherence and drug failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/20492660

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pneumocystis carinii Pneumonia Recurrence in HIV Patients on Highly Active Antiretroviral Therapy: Secondary Prophylaxis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20492660

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cotrimoxazole prophylaxis in HIV-infected individuals after completing anti-tuberculosis treatment in Thyolo, Malawi

1 reference

https://pubmed.ncbi.nlm.nih.gov/20492660

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Discontinuation of primary prophylaxis against Mycobacterium avium complex infection in HIV-infected persons receiving antiretroviral therapy: observations from a large national cohort in the United States, 1992-2002

1 reference

https://pubmed.ncbi.nlm.nih.gov/20492660

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells/??l when viral replication is suppressed

1 reference

https://pubmed.ncbi.nlm.nih.gov/20492660

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2334-10-126

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33584240&oldid=2195523248"